BioLingus (Sublingual Tablets)
BioLingus has developed a novel proprietary platform for sublingual delivery of bio-active molecules for chronic diseases and immune-therapies.
The BioLingus platform uses micro-encapsulation technology optimised for sublingual delivery of bio-active molecules such as proteins, peptides, and small molecules.
The platform is the result of more than a decade of research and development and multiple technology generations which have resulted in:
- Optimised and stable formulation
- Optimised and robust process
- Innovative custom built equipment engineering of the granular design
BioLingus technology has been tested on mice and has proven to match subcutaneous injection, both in terms of efficacy and low variability.
Major advantages of the BioLingus technology are its scalability and ability to provide relatively low-cost product which has long shelf life.
BioLingus has been selected as the winner of the 2016 AWARD in the category 'MOST INNOVATIVE BIOTECH COMPANY' by the European CEO magazine.
Awards will be presented during the 2017 World Economic Forum Meeting (WEF) in Davos Switzerland.